Abstract: OBJECTIVE To explore the relationship between the strength and weakness of the important adverse reaction signals of these drugs, the adverse reactions of sodium-glucose cotransporter-2 inhibitors(canagliflozin, dapagliflozin and empagliflozin) were mined through the FDA Adverse Events Reporting System(FAERS) database, and to provide a basis for clinical safe medication. METHODS The FAERS database was retrieved from the second quarter of 2013 to the fourth quarter of 2019 for a total of 27 quarters regarding six major adverse reactions to sodium-glucose cotransporter-2 inhibitors. The measurse of disproportionality include reporting odds ratio and proportional reporting ratio were used for signal detection, further study the strongest warning signal, and five factors including gender, age, dose, indications and medication time were analyzed. RESULTS According to the calculation of the signal value, in terms of hypotension, empagliflozin> canagliflozin>dapagliflozin; in terms of diabetic ketoacidosis, empagliflozin>canagliflozin>dapagliflozin; for acute kidney injury/renal injury, canagliflozin>dapagliflozin>empagliflozin; for genital fungal infections, canagliflozin>dapagliflozin> empagliflozin; for urinary tract infections, dapagliflozin>canagliflozin>empagliflozin; in terms of elevated low-density cholesterol, dapagliflozin>canagliflozin>empagliflozin. CONCLUSION The mining of FAERS data can be used to comprehensively and deeply analyze and study the main adverse reactions of sodium-glucose cotransporter-2 after it is marketed, thereby effectively reducing the risk of clinical medication.